# Belantamab mafodotin

Source: https://onco.cc/drugs/belantamab-mafodotin/  
OnCo record `belantamab-mafodotin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.

## Summary

Belantamab mafodotin is an afucosylated anti-BCMA IgG1 antibody linked through a non-cleavable linker to MMAF, a non-permeable tubulin inhibitor; it kills through the payload and through enhanced antibody-dependent cellular cytotoxicity. It received accelerated approval in 2020 for myeloma after four or more lines (DREAMM-2), was withdrawn in 2022 when DREAMM-3 failed to confirm benefit, and returned in 2025 in the US and EU for relapsed or refractory myeloma after at least one prior line, after DREAMM-7 (with bortezomib and dexamethasone) and DREAMM-8 (with pomalidomide and dexamethasone) showed progression-free and overall survival benefits. Dosing is 2.5 mg/kg every 3 weeks in DREAMM-7 or 2.5 then 1.9 mg/kg every 4 weeks in DREAMM-8. Keratopathy occurs in most patients and carries a boxed warning, so an ophthalmology-based REMS is required.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Blenrep
- Modality: ADC
- Mechanism: Afucosylated anti-BCMA IgG1 with MMAF; ADCC plus payload.
- Payload: MMAF (tubulin inhibitor, non-permeable)
- Linker: mc, non-cleavable
- Approvals: US 2020: Relapsed myeloma ≥4 lines (accelerated; withdrawn 2022); US 2025: Relapsed/refractory myeloma after ≥1 prior line, in combination; EU 2025: R/R myeloma with BorDex or PomDex; 23 Jul 2025
- Dosing: IV infusion; 2.5 mg/kg every 3 weeks with bortezomib/dexamethasone (DREAMM-7) or 2.5 mg/kg then 1.9 mg/kg every 4 weeks with pomalidomide/dexamethasone (DREAMM-8)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Belantamab_mafodotin
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Belantamab%20mafodotin

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [GSK](https://onco.cc/companies/gsk/)
- terms: [Indication withdrawal](https://onco.cc/terms/approval-withdrawal/), [Maleimidocaproyl (mc), non-cleavable](https://onco.cc/terms/mc-non-cleavable/), [MMAF](https://onco.cc/terms/mmaf/), [Ocular toxicity (keratopathy, blurred vision)](https://onco.cc/terms/ocular-toxicity/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- trials: [A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas](https://onco.cc/trials/nct06679101/), [A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult](https://onco.cc/trials/nct07227311/), [A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme](https://onco.cc/trials/nct05714839/), [All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo](https://onco.cc/trials/nct06956170/), [China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame](https://onco.cc/trials/nct06868654/), [DREAMM-7](https://onco.cc/trials/dreamm-7/), [DREAMM-8](https://onco.cc/trials/dreamm-8/), [Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex](https://onco.cc/trials/nct06868667/), [Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04126200/), [Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04162210/), [Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi](https://onco.cc/trials/nct07150104/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM](https://onco.cc/trials/nct07217119/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM](https://onco.cc/trials/nct07217184/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM](https://onco.cc/trials/nct07084896/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM](https://onco.cc/trials/nct07150091/)
- people: [Sagar Lonial](https://onco.cc/people/sagar-lonial/)
- biomarkers: [BCMA expression](https://onco.cc/biomarkers/bcma-expression/)

---
JSON: https://onco.cc/api/v1/entities/belantamab-mafodotin.json